Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andres Valkna is active.

Publication


Featured researches published by Andres Valkna.


Neuroscience Letters | 1995

Differential regulation of adenylate cyclase activity in rat ventral and dorsal hippocampus by rat galanin

Andres Valkna; Anders Juréus; Ello Karelson; Mihkel Zilmer; Tamas Bartfai; Ülo Langel

Rat galanin inhibits basal as well as forskolin-stimulated adenylate cyclase activity in rat ventral and dorsal hippocampus. The inhibition of adenylate cyclase activity, both basal and forskolin-stimulated, is characterised by IC50 values being 250-fold lower in ventral hippocampus (IC50 = 1.1 nM) compared to the dorsal hippocampus (IC50 = 270 nM). The maximal inhibition of basal and forskolin-stimulated adenylate cyclase activity in both ventral and dorsal hippocampus in the presence of 10 microM rat galanin is 34-45%. The analysis of the binding data obtained with 125I-labelled Tyr26-porcine galanin as a tracer reveals similar binding constants for rat galanin in both ventral and dorsal hippocampus with 4.8-fold higher concentration of galanin receptors in the ventral hippocampus. Putative galanin receptor subtype differences between the ventral and dorsal hippocampus have been noted by Hedlund et al. (Eur. J. Pharmacol., 224 (1992) 203-205). This study yields further confirmation for the existence of different galanin receptor subtypes or for differential coupling of galanin receptors to the adenylate cyclase in the dorsal versus ventral hippohampus.


Neuropeptides | 2000

Role of third intracellular loop of galanin receptor type 1 in signal transduction

Khadijeh Rezaei; Külliki Saar; Ursel Soomets; Andres Valkna; J. Näsman; M. Zorko; K. Åkerman; T. Schroeder; Tamas Bartfai; Ülo Langel

To determine the domains essential for G-protein coupling of the human galanin receptor type 1 (GalR1), we have used both GalR1 mutants and synthetic receptor-derived peptides in(125)I-galanin and [(35)S]-GTPgammaS binding studies. Replacement of potential phosphorylation sites by Leu in the third intracellular loop (IC3) of GalR1 did not affect K(D)values for the receptor. Peptides derived form the IC3 loop, and especially the N-terminal part of it were able to increase the rate of [(35)S]-GTPgammaS binding to the trimeric Gialpha1beta1gamma2, but not to Gsalphabeta1gamma2, whereas the peptides corresponding to the IC1 and IC2 loops had no such effect. IC3 loop peptides also inhibited the binding of(125)I-galanin to GalR1 in membranes from Rin m5F cells. Our results suggest that the IC3 loop of GalR1, especially its N-terminal part, defines the coupling of the receptor to the Gialpha1beta1gamma2 protein and consequently, to the signal transduction cascade.


Regulatory Peptides | 2001

Characterisation of a new chimeric ligand for galanin receptors: galanin(1–13)-[d-Trp32]-neuropeptide Y(25–36)amide

Külliki Saar; Riina Mahlapuu; Erki Laidmäe; Andres Valkna; Ulrika Kahl; Ello Karelson; Ülo Langel

In this work, we studied a novel chimeric peptide, M242, galanin(1-13)-[D-Trp(32)]-neuropeptide Y(25-36)amide, and examined its properties in comparison with its parent peptide, M32, galanin(1-13)-neuropeptide Y(25-36)amide, a previously known high-affinity ligand for galanin receptors, and galanin itself. Binding assays performed in Bowes cells known to express human galanin receptor type 1 (hGalR1) and in Chinese hamster ovary cells overexpressing human galanin receptor type 2 (hGalR2) revealed that all three ligands had comparable affinities: at hGalR1<1 nM and at hGalR2<10 nM. However, in rat hippocampal membranes M242 had a 24-fold lower affinity than galanin (9.4 vs. 0.4 nM) and 134-fold lower affinity than M32 (9.4 vs. 0.07 nM). In the same tissue, we also examined the effects of these peptides on adenylate cyclase activity. M32 showed a weak antagonistic behaviour but M242 acted as a potent biphasic regulator of adenylate cyclase. In conclusion, we present and characterise a new peptide M242, which could be a useful tool in studies of galaninergic signalling.


Hybridoma | 2008

Generation and Characterization of a Single-Chain Fv Antibody Against Gli3, a Hedgehog Signaling Pathway Transcription Factor

Silja Laht; Kati Meerits; Harri Altroff; Helena Faust; Robert Tsaney; Priit Kogerman; Lilian Järvekülg; Viiu Paalme; Andres Valkna; Sirje Timmusk

Gli3 is a key regulator of development, controlling multiple patterning steps. Here we report the generation of a scFv antibody specific to the repressor domain of human Gli3. We show that this scFv retains the binding capacity of its parent anti-Gli3 monoclonal antibody derived from hybridoma clone 5E1. When expressed in mammalian cells, the anti-Gli3 scFv co-localizes with intracellular Gli3. Immunocytochemical staining of the intrabody in Gli3-positive TM4 cells shows a distinct perinuclear cytoplasmic localization. Such a scFv constitutes a useful tool for studying transcriptional regulation of the hedgehog pathway in mammals and offers a starting point for developing novel Gli-related therapeutic intrabodies.


Nature Biotechnology | 1998

Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo

Margus Pooga; Ursel Soomets; Mattias Hällbrink; Andres Valkna; Külliki Saar; Khadijeh Rezaei; Ulrika Kahl; Jing-Xia Hao; Xiao-Jun Xu; Zsuzsanna Wiesenfeld-Hallin; Tomas Hökfelt; Tamas Bartfai; Ülo Langel


Journal of Controlled Release | 2005

Evaluation of transportan 10 in PEI mediated plasmid delivery assay.

Kalle Kilk; Samir El-Andaloussi; Peter Järver; Anne Meikas; Andres Valkna; Tamas Bartfai; Priit Kogerman; Madis Metsis; Ülo Langel


Archive | 1998

Membrane-permeable constructs for transport across a lipid membrane

Ülo Langel; Tamas Bartfai; Margus Pooga; Andres Valkna; Külliki Saar; Mattias Hällbrink


Archive | 1998

Conjugates of transporter peptides and nucleic acid analogs, and their use

Ülo Langel; Tamas Bartfai; Margus Pooga; Andres Valkna; Külliki Saar; Mattias Hällbrink


Hybridoma | 2007

Generation and Characterization of Mouse Monoclonal Antibody 5E1 Against Human Transcription Factor GLI3

Reet Hunt; Olga Bragina; Monika Drews; Lagle Kasak; Sirje Timmusk; Andres Valkna; Priit Kogerman; Lilian Järvekülg


Archive | 2008

NOVEL INHIBITOR OF ANGIOGENESIS

Taavi Päll; Wally Andderson; Lagle Kasak; Anne Pink; Priit Kogerman; Aire Allikas; Andres Valkna

Collaboration


Dive into the Andres Valkna's collaboration.

Top Co-Authors

Avatar

Tamas Bartfai

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Priit Kogerman

National Institute of Chemical Physics and Biophysics

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ülo Langel

University Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Anne Pink

Tallinn University of Technology

View shared research outputs
Top Co-Authors

Avatar

Lagle Kasak

Tallinn University of Technology

View shared research outputs
Top Co-Authors

Avatar

Taavi Päll

Tallinn University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lilian Järvekülg

National Institute of Chemical Physics and Biophysics

View shared research outputs
Researchain Logo
Decentralizing Knowledge